Critical Survey: OmniAb (NASDAQ:OABI) and Caris Life Sciences (NASDAQ:CAI)

Caris Life Sciences (NASDAQ:CAI – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Caris Life Sciences has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Valuation and Earnings

This table compares Caris Life Sciences and OmniAb”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Caris Life Sciences $812.03 million 6.89 -$68.09 million $0.33 59.09
OmniAb $40.21 million 18.43 -$64.78 million ($0.34) -14.94

OmniAb has lower revenue, but higher earnings than Caris Life Sciences. OmniAb is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Caris Life Sciences and OmniAb, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caris Life Sciences 1 5 8 0 2.50
OmniAb 1 0 3 0 2.50

Caris Life Sciences presently has a consensus target price of $31.18, suggesting a potential upside of 59.91%. OmniAb has a consensus target price of $11.50, suggesting a potential upside of 126.38%. Given OmniAb’s higher possible upside, analysts plainly believe OmniAb is more favorable than Caris Life Sciences.

Institutional & Insider Ownership

72.1% of OmniAb shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Caris Life Sciences and OmniAb’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caris Life Sciences 9.16% 16.00% 8.05%
OmniAb -108.11% -16.74% -14.79%

Summary

Caris Life Sciences beats OmniAb on 9 of the 13 factors compared between the two stocks.

About Caris Life Sciences

(Get Free Report)

Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.

About OmniAb

(Get Free Report)

OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.

Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.